Antithrombotic materials and methods

Details Antithrombotic materials and methods Antithrombotic materials and methods

1999-04-26

2000-08-22

Low, Christopher S. F.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 21, 514822, 530324, 530350, 530829, 424529, 424532, A61K 3800, A61K 3816

Patent

active

06107280&

ABSTRACT:
Antithrombotic materials and methods are provided for the treatment of thrombotic disorders, in which therapeutically effective amounts of BPI protein products are administered.

REFERENCES:
patent: 5089274 (1992-02-01), Marra et al.
patent: 5171739 (1992-12-01), Scott et al.
patent: 5198541 (1993-03-01), Elsbach et al.
patent: 5234912 (1993-08-01), Marra et al.
patent: 5308834 (1994-05-01), Scott et al.
patent: 5334584 (1994-08-01), Scott et al.
patent: 5348942 (1994-09-01), Little, II et al.
patent: 5420019 (1995-05-01), Theofan et al.
patent: 5439807 (1995-08-01), Grinna
patent: 5447913 (1995-09-01), Ammons et al.
patent: 5466580 (1995-11-01), White et al.
patent: 5466581 (1995-11-01), White et al.
patent: 5488034 (1996-01-01), McGregor et al.
patent: 5494896 (1996-02-01), Hansbrough
patent: 5523288 (1996-06-01), Cohen et al.
patent: 5532216 (1996-07-01), Espevik et al.
patent: 5576292 (1996-11-01), Elsbach et al.
patent: 5578568 (1996-11-01), Ammons et al.
patent: 5578572 (1996-11-01), Horwitz et al.
patent: 5741779 (1998-04-01), White et al.
Carr et al., "Granulocyte lysosomal cationic protein alters fibrin assembly: A possible mechanism for granulocyte control of clot structure," J. Lab. Clin. Med., 107:199-203 (1986).
Carr et al., "Large Fibrin Fibers Enhance Urokinase-Induced Plasmin Digestion of Plasma Clots," 29th Ann. Meeting Am. Soc. Hematol., Blood, 70(Suppl. 1):400a (1987).
Carr et al., "Platelet Factor 4 Enhances Fibrin Fiber Polymerization," Thrombosis Research, 45:539-543 (1987).
Carr et al., "Effects of Poloxamer 188 on the Assembly, Structure and Dissolution of Fibrin Clots," Thrombosis and Haemostasis, 66(5):565-568 (1991).
Cecil's Textbook of Medicine, 17th Edition, W.B. Saunders Co., Pennsylvania, pp. 1053-1058 (1985).
Chapter 52, "Coagulation Disorders," Cecil's Essentials of Medicine, 3rd Edition, W.B. Saunders Co., Pennsylvania, pp. 408-416 (1983).
Elsbach and Weiss, in Inflammation: Basic Principles and Clinical Correlates, Gallin et al., Eds., Chapter 30, Raven Press, Ltd. (1992).
Elsbach et al., "Separation and Purification of a Potent Bactericidal/Permeability Increasing Protein and a Closely Associated Phospholipase A.sub.2 From Rabbit Polymorphonuclear Leukocytes," J. Biol. Chem., 254(21):11000-11009 (1979).
Fears, R., "Kinetic studies on the effect of heparin and fibrin on plasminogen activators," Biochem. J., 249:77-81 (1988).
Gazzano-Santoro et al., "High-Affinity Binding of the Bactericidal/Permeability-Increasing Protein and a Recombinant Amino-Terminal Fragment to the Lipid A Region of Lipopolysaccharide," Infect. Immun. 60(11):4754-4761 (1992).
Gray et al., "Cloning of the cDNA of a Human Neutrophil Bactericidal Protein," J. Biol. Chem., 264(16):9505-9509 (1989).
Heyderman et al., "Is there a circulating anticoagulant in meningococcal disease," Proc. Brit. Paediatric Association, p. 40 (Abstract G13) (Apr. 17, 1991).
Hogg and Jackson, "Fibrin monomer protects thrombin from inactivation by heparin-antithrombin III: Implications for heparin efficacy," Proc. Nat'l Acad. Sci., USA, 86:3619-3623 (1989).
Hogg and Jackson, "Formation of a Ternary Complex between Thrombin, Fibrin Monomer, and Heparin Influences the Action of Thrombin on Its Substrates," J. Biol. Chem., 265(1):248-255 (1990).
Hogg and Jackson, "Heparin Promotes the Binding of Thrombin to Fibrin Polymer," J. Biol. Chem., 265(1):241-247 (1990).
Klement et al., "The Effect of Thrombin Inhibitors on Tissue Plasminogen Activator Induced Thrombolysis in a Rat Model," Thrombosis & Haemostasis, 68:64-68 (1992).
Majerus et al., Chapter 54, "Anticoagulant, Thrombolytic and Antiplatelet Drugs," Goodman & Gilman, The Pharmacological Basis of Therapeutics, 9th Edition, McGraw-Hill, NY, pp. 1341-1358 (1996).
Nenci et al., "Fibrin clots obtained from plasma containing heparin show a higher sensitivity to t-PA-induced lysis," Blood Coagulation and Fibrinolysis, 3:279-285 (1992).
Odrljin et al., "Thrombin Cleavage Enhances Exposure of a Heparin Binding Domain in the N-Terminus of the Fibrin .beta. Chain," Blood, 88(6):2050-2061 (1996).
Ooi et al., "A 25-kDa NH.sub.2 -Terminal Fragment Carries All the Antibacterial Activities of the Human Neutrophil 60-kDa Bactericidal/Permeability-Increasing Protein," J. Biol. Chem., 262(31):14891-14894 (1987).
Ooi et al., "Endotoxin Neutralizing Properties of the 25 kD N-Terminal Fragment of the 55-60 kD Bactericidal/Permeability-Increasing Protein of Human Neutrophils," J. Exp. Med., 174:649-655 (1991).
Parise et al., "Effects of low molecular weight heparins on fibrin polymerization and clot sensitivity to t-PA-induced lysis," Blood Coagulation and Fibrinolysis, 4:721-727 (1993).
Retzinger et al., "Complexation with Heparin Prevents Adhesion between Fibrin-coated Surfaces," J. Biol. Chem., 267(34):24356-24362 (1992).
Suffredini et al., "Promotion and Subsequent Inhibition of Plasminogen Activation After Administration of Intravenous Endotoxin to Normal Subjects," New Engl. J. Med., 320(18):1165-1172 (1989).
von der Mohlen et al., "Inhibition of Endotoxin-Induced Activation of the Coagulation and Fibrinolytic Pathways Using a Recombinant Endotoxin-Binding Proetin (rBPI.sub.23)," Blood, 85(12):3437-3443 (1995).
Weiss et al., "Cellular and Subcellular Localization of the Bactericidal/Permeability-Increasing Protein of Neutrophils," Blood, 69(2):652-659 (1987).
Bode et al., "Combinations of thrombolytic agents in acute myocardial infarction," Zeitschnift for Kardiologie, vol. 82 (Suppl. 2) 125-128 (1993).
Olsson et al., "Early Intravenous Beta Blockade and Thrombolytics in Acute Myocardial Infarction," Amer. J. Cardiology, vol. 72, No. 19 156G-169G (1993).

Affiliated with

Also associated with

Rating

Antithrombotic materials and methods does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Antithrombotic materials and methods, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Antithrombotic materials and methods will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-581232